Company: HCWB
Filing Date: 2025-02-11
Form Type: PRE 14A
Source: 0001193125-25-024372
Chunk: 5

Company: HCW Biologics Inc.
Filing Date: 2025-02-11
Form: PRE 14A
Chunk 5
---
 Notice of Special Meeting of Stockholders; |

| • |     | The Proxy Statement; and |

| • |     | [APPENDICES] |

If you received printed versions of these materials by mail (rather than through electronic delivery), the materials also included a proxy card or voting instruction form. 1

| Q: | What proposals are scheduled to be voted on at the meeting? |

| A: | Stockholders will be asked to vote on the following three proposals at the meeting, each of which are, among 
 other things, part of the Company’s plan to regain compliance with applicable Nasdaq listing requirements:   |

| 1. | To approve an amendment to the Company’s certificate of incorporation on or before the one (1) year                                                                                                                                           
 anniversary of the Special Meeting, to implement one or more reverse stock splits of the outstanding shares of the Company’s common stock (as necessary to maintain a listing of the Company’s common stock, par value $0.0001 per share (our 
 “Common Stock”) on the Nasdaq Capital Market) in a range from one-for-twenty (1:20) up to                                                                                                                                                     
 one-for-fifty (1:50), or anywhere between (the “Reverse Stock Split”), without changing the number of authorized shares of our Common Stock required for Nasdaq                                                                               
 listing which is 150,000,000 shares, all as determined in the sole discretion of the Company’s Board of Directors (the “Reverse Stock Split Proposal”) (“Proposal One”); and                                                                  |

| 2. | To approve for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of our                                                                                                                                    
 common stock, or such lesser number of shares as the Board of Directors determines, pursuant to that certain Common Stock Purchase Agreement, dated _______, 2025 (the “Purchase Agreement”) and that certain Registration Rights Agreement, 
 dated _______, 2025 (the “Rights Agreement”) entered into in connection with an equity line of credit with _____________ (the “ELOC”) (“Proposal Two”); and                                                                                  |

| 3. | To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our Common                                                                                                                                   
 Stock upon conversion of up to $6,905,000 of principal amount of Senior Secured Notes issued by the Company to certain investors therein, including certain officers, directors and stockholders of the Company (collectively, the             
 “Noteholders”), pursuant to that certain Amended